Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Secretagogin Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:SCGN, SECRET
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

Availability on Request RD191120200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-EDTA

Sample Requirements

50 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

62.5–2000 pg/ml

Limit of Detection

11 pg/ml

Intra-assay (Within-Run)

CV = 6.0%

Inter-assay (Run-to-Run)

CV = 6.5%

Spiking Recovery


Dilution Linearity




  • It is intended for research use only
  • The total assay time is less than 3.5 hours
  • The kit measures human secretagogin in serum and plasma (EDTA)
  • Quality Controls are human serum based. No animal sera are used
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Diabetology - Other Relevant Products, Neural tissue markers, Oncology


Secretagogin (SCGN, SEGN, CALBL, setagin) is a Ca-binding protein which consists of six-EF hand Ca-binding domains and is characterised by molecular weight of 32 kDa. Generally, Ca-binding proteins seem to be involved in several pathological conditions in the CNS, such as epilepsy or neurodegenerative disorders, for example Alzheimer´s disease. Secretagogin is expressed in central nervous system, particularly in the cerebellum, pituitary gland and hypotalamus, but also in thalamic tissue. Moreover, recent study shown, that secretagogin is detectable in human serum after ischemic brain damage. The secretagogin mRNA was identified as one of the most abundant transcripts in pancreatic islets, highlighting the potential importance of secretagogin in this tissue.
Secretagogin is down-regulated in pancreatic islets exposed to high concentration of glucose, in human non-functional pituitary adenomas and in adenocarcinomas. These results suggest that secretagogin may be involved in suppressing cell growth, and it has been proposed as a novel biomarker for diagnosis of different forms of cancer. Additionally, its strong expression in insulin secreting cells, its influence on insulin expression
might contribute to insulin homeostasis.
Areas of investigation: Neurodegenerative disease, Brain injury, Insulin secretion and Cancer.

Product References (2)


  • Hansson SF, Zhou AX, Vachet P, Eriksson JW, Pereira MJ, Skrtic S, JongsmaWallin H, Ericsson-Dahlstrand A, Karlsson D, Ahnmark A, Sörhede Winzell M,Magnone MC, Davidsson P. Secretagogin is increased in plasma from type 2 diabetespatients and potentially reflects stress and islet dysfunction. PLoS One. 2018Apr 27;13(4):e0196601. doi: 10.1371/journal.pone.0196601. eCollection 2018.PubMed PMID: 29702679; PubMed Central PMCID: PMC5922551. See more on PubMed
  • Willett WC. Epidemiologic studies of diet and cancer. Prog Clin Biol Res.1990;346:159-68. Review. PubMed PMID: 2197623. See more on PubMed
Summary References (8)

References to Secretagogin

  • Adolf K, Wagner L, Bergh A, Stattin P, Ottosen P, Borre M, Birkenkamp-Demtroder K, Orntoft TF, Torring N. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate. 2007 Apr 1;67 (5):472-84
  • Gartner W, Lang W, Leutmetzer F, Domanovits H, Waldhausl W, Wagner L. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex. 2001 Dec;11 (12):1161-9
  • Gartner W, Vila G, Daneva T, Nabokikh A, Koc-Saral F, Ilhan A, Majdic O, Luger A, Wagner L. New functional aspects of the neuroendocrine marker secretagogin based on the characterization of its rat homolog. Am J Physiol Endocrinol Metab. 2007 Jul;293 (1):E347-54
  • Gartner W, Zierhut B, Mineva I, Sodeck G, Leutmezer F, Domanovits H, Prayer D, Wolf F, Base W, Weissel M, Wagner L. Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. Clin Biochem. 2008 Dec;41 (18):1434-9
  • Lai M, Lu B, Xing X, Xu E, Ren G, Huang Q. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A. Virchows Arch. 2006 Oct;449 (4):402-9
  • Pipp I, Wagner L, Rossler K, Budka H, Preusser M. Secretagogin expression in tumours of the human brain and its coverings. APMIS. 2007 Apr;115 (4):319-26
  • Rogstam A, Linse S, Lindqvist A, James P, Wagner L, Berggard T. Binding of calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin. Biochem J. 2007 Jan 1;401 (1):353-63
  • Wagner L, Oliyarnyk O, Gartner W, Nowotny P, Groeger M, Kaserer K, Waldhausl W, Pasternack MS. Cloning and expression of secretagogin, a novel neuroendocrine- and pancreatic islet of Langerhans-specific Ca2+-binding protein. J Biol Chem. 2000 Aug 11;275 (32):24740-51
Related Products Docs